Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

Nicole E. Marshall, Karla V. Ballman, John C. Michalak, Paula J. Schomberg, Gary V. Burton, Howard M. Sandler, Terrence L. Cascino, Kurt Jaeckle, Jan C. Buckner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic toxicities were recorded at each visit. Results: 56% of patients had hearing loss at baseline. 13% and 50% of patients experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13% of those on arms C and D experiencing significant ototoxicity (≥ grade 3) at 6 months. Increasing age was associated with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.

Original languageEnglish (US)
Pages (from-to)315-320
Number of pages6
JournalJournal of Neuro-Oncology
Volume77
Issue number3
DOIs
StatePublished - May 1 2006

Fingerprint

Glioblastoma
Cisplatin
Carmustine
Radiotherapy
Hearing Loss

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Marshall, N. E., Ballman, K. V., Michalak, J. C., Schomberg, P. J., Burton, G. V., Sandler, H. M., ... Buckner, J. C. (2006). Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. Journal of Neuro-Oncology, 77(3), 315-320. https://doi.org/10.1007/s11060-005-9049-1
Marshall, Nicole E. ; Ballman, Karla V. ; Michalak, John C. ; Schomberg, Paula J. ; Burton, Gary V. ; Sandler, Howard M. ; Cascino, Terrence L. ; Jaeckle, Kurt ; Buckner, Jan C. / Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. In: Journal of Neuro-Oncology. 2006 ; Vol. 77, No. 3. pp. 315-320.
@article{642c0b420b36485c9addf9ad00d755ca,
title = "Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients",
abstract = "Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic toxicities were recorded at each visit. Results: 56{\%} of patients had hearing loss at baseline. 13{\%} and 50{\%} of patients experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13{\%} of those on arms C and D experiencing significant ototoxicity (≥ grade 3) at 6 months. Increasing age was associated with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.",
author = "Marshall, {Nicole E.} and Ballman, {Karla V.} and Michalak, {John C.} and Schomberg, {Paula J.} and Burton, {Gary V.} and Sandler, {Howard M.} and Cascino, {Terrence L.} and Kurt Jaeckle and Buckner, {Jan C.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1007/s11060-005-9049-1",
language = "English (US)",
volume = "77",
pages = "315--320",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Marshall, NE, Ballman, KV, Michalak, JC, Schomberg, PJ, Burton, GV, Sandler, HM, Cascino, TL, Jaeckle, K & Buckner, JC 2006, 'Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients', Journal of Neuro-Oncology, vol. 77, no. 3, pp. 315-320. https://doi.org/10.1007/s11060-005-9049-1

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. / Marshall, Nicole E.; Ballman, Karla V.; Michalak, John C.; Schomberg, Paula J.; Burton, Gary V.; Sandler, Howard M.; Cascino, Terrence L.; Jaeckle, Kurt; Buckner, Jan C.

In: Journal of Neuro-Oncology, Vol. 77, No. 3, 01.05.2006, p. 315-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

AU - Marshall, Nicole E.

AU - Ballman, Karla V.

AU - Michalak, John C.

AU - Schomberg, Paula J.

AU - Burton, Gary V.

AU - Sandler, Howard M.

AU - Cascino, Terrence L.

AU - Jaeckle, Kurt

AU - Buckner, Jan C.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic toxicities were recorded at each visit. Results: 56% of patients had hearing loss at baseline. 13% and 50% of patients experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13% of those on arms C and D experiencing significant ototoxicity (≥ grade 3) at 6 months. Increasing age was associated with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.

AB - Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic toxicities were recorded at each visit. Results: 56% of patients had hearing loss at baseline. 13% and 50% of patients experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13% of those on arms C and D experiencing significant ototoxicity (≥ grade 3) at 6 months. Increasing age was associated with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.

UR - http://www.scopus.com/inward/record.url?scp=33748416787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748416787&partnerID=8YFLogxK

U2 - 10.1007/s11060-005-9049-1

DO - 10.1007/s11060-005-9049-1

M3 - Article

C2 - 16273313

AN - SCOPUS:33748416787

VL - 77

SP - 315

EP - 320

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -